V540 D
Alternative Names: V-540DLatest Information Update: 16 Jan 2025
Price :
$50 *
At a glance
- Originator Merck Sharp & Dohme
- Class Papillomavirus vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Human papillomavirus infections
Most Recent Events
- 20 Dec 2024 Phase-I clinical trials in Human papillomavirus infections (In volunteers, Prevention) in USA (IM) (NCT06688058)
- 22 Nov 2024 Preclinical trials in Human papillomavirus infections in USA (IM)
- 22 Nov 2024 Merck Sharp and Dohme plans a phase I trial for Human papilloma virus infections (Prevention) in December 2024 (NCT06688058)